Search
forLearn
5 / 801 resultslearn sh-Polypeptide-7
learn zinc PCA
learn oligopeptide-71
learn phosphorus
Research
5 / 70 results
research ROBO4 deletion ameliorates PAF-mediated skin inflammation via regulating the mRNA translation efficiency of LPCAT1/LPCAT2 and the expression of PAF receptor
Removing the ROBO4 gene in mice reduces skin inflammation and hair loss by affecting certain inflammation pathways and gene expression.
research Drug repositioning using in silico compound profiling
Using computers to analyze drugs can find new uses for them, but actual experiments are needed to confirm these uses.
research Non-Edg family LPA receptors: the cutting edge of LPA research
New LPA receptors (LPA4, LPA5, LPA6) have diverse roles in the body.
research Understanding the role of prostaglandin E2 in regulating human platelet activity in health and disease
Prostaglandin E2 affects human platelet activity in complex ways that could lead to personalized heart disease treatments.
research Anti-androgenic effect of sesquiterpenes isolated from the rhizomes of Curcuma aeruginosa Roxb.
Germacrone from Curcuma aeruginosa may help treat conditions related to male hormones by blocking a specific enzyme.
Community Join
5 / 1000+ resultscommunity Protac degradation of the androgen receptor in mice shows good efficacy and no systemic drug could be found
The efficacy of degrading the androgen receptor through dermal application in DP cells, a delivery system for topical drugs that involves dissolving microneedles, and rosemary oil as an alternative anti-androgen.
community Fevipiprant 2019!
The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.